Advancing patient care in neurodegenerative diseases with unmet medical needs

AstraZeneca is committed to discovering and developing compounds to improve patient care in neuroscience.

With a rich heritage and a research and development focus on specific aspects of neurodegenerative diseases, analgesia and psychiatry, AstraZeneca continues to push the boundaries of science in neuroscience in collaboration with other innovative partners across industry and academia. A significant unmet medical need remains in the areas of cognitive disorders, chronic pain and other central nervous system disorders. 


Collaboration stories

Partnering with influential organisations to extend the reach of our science to more patients and healthcare providers

Our focus on unmet medical needs

More than 450 million people worldwide are affected by mental, neurological or behavioural problems, and the number is steadily rising.

  • Opioid-induced constipation (OIC)

    OIC is a condition caused by prescription opioid pain medicines. Millions of patients are treated with opioids each year.

  • Alzheimer's disease (AD)

    AD is a fatal illness that causes progressive decline in memory and other aspects of cognition.

Opportunities for collaboration

Kate's story

What we're working on

We are committed to developing novel therapies that advance the science of neurodegenerative diseases and have the potential to provide a positive impact on patients around the world.

        Image: Artistic rendering of BACE enzyme.

Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Infection, Neuroscience and Gastrointestinal (as at 28 July 2016)

Phase 1

Phase 1

  • AZD8108 suicidal ideation
  • MEDI1814 Alzheimer’s disease
  • MEDI7352 osteoarthritis pain

Phase 2

Phase 2

  • ATM AVI targeted serious bacterial infections
  • AZD3241 multiple system atrophy
  • MEDI3902 prevention of nosocomial pseudomonas pneumonia
  • MEDI4893 hospital-acquired pneumonia/serious S. aureus infection
  • MEDI7510 prevention of RSV disease in older adults
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis

Phase 3/Reg.*

Phase 3/Reg.*

  • AZD3293 AMARANTH Early Alzheimer's disease
  • CAZ AVI serious infections, complicated intraabdominal infection, complicated urinary tract infection
  • CAZ AVI hospital-acquired pneumonia/ ventilator-associated pneumonia
  • MEDI-550 pandemic influenza prophylaxis
  • Zinforo pneumonia/skin infections

LCM Projects

LCM Projects

  • Nexium stress ulcer prophylaxis
  • Nexium paediatrics
  • linaclotide irritable bowel syndrome with constipation (IBS-C)

Our medicines

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

  • Diprivan propofol
  • Movantik/Moventig naloxegol
  • Naropin ropivacaine
  • Seroquel IR quetiapine fumarate
  • Seroquel XR quetiapine fumarate
  • Xylocaine lidocaine
  • Zomig, Zomig Rapimelt, Zomig Nasal Spray, AscoTop, Zomigon zolmitriptan


Events and talks

Hear more about our data, products, and pipeline


Upcoming events

We have no upcoming events at the moment. Please look again soon as events will be added nearer to the time.

Page Atlas ID: 958747.011
Date of next review: March 2017